First-class delivery: Getting growth factors to their destination

Journal of Investigative Dermatology

Volumn 128, Issue 6, 2008, Pages 1360-1362

  Davidson, Jeffrey M ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; KERATINOCYTE GROWTH FACTOR;

BIOAVAILABILITY; CELL THERAPY; COST EFFECTIVENESS ANALYSIS; EXTRACELLULAR MATRIX; GENE DELIVERY SYSTEM; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; VIRION; WOUND HEALING;

EID: 43749094102     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2008.128     Document Type: Note

References (15)

1. J. Doukas L.A. Chandler A.M. Gonzalez D. Gu D.K. Hoganson C. Ma Matrix immobilization enhances the tissue repair activity of growth factor gene therapy vectors Hum Gene Ther 12 2001 783 798
2. S.A. Eming T. Krieg J.M. Davidson Gene therapy and wound healing Clin Dermatol 25 2007 79 92
3. M.J. Escámez M. García F. Larcher A. Meana E. Munoz J.L. Jorcano An in vivo model of wound healing in genetically modified skin-humanized mice J Invest Dermatol 123 2004 1182 1191
4. M.J. Escámez M. Carretero M. García L. Martínez-Santamaría I. Mirones B. Duarte Assessment of optimal virus-mediated growth factor gene delivery for human cutaneous wound healing enhancement J Invest Dermatol 128 2008 1565 1575
5. D.L. Gu T. Nguyen A.M. Gonzalez M.A. Printz G.F. Pierce B.A. Sosnowski Adenovirus encoding human platelet-derived growth factor-B delivered in collagen exhibits safety, biodistribution, and immunogenicity profiles favorable for clinical use Mol Ther 9 2004 699 711
6. R. Lanza R. Langer J. Vacanti Principles of Tissue Engineering 3rd edn. 2007 Elsevier Boston
7. P.J. Leahy W.T. Lawrence Biologic enhancement of wound healing Clin Plast Surg 34 2007 659 671
8. D.J. Margolis T. Crombleholme M. Herlyn Clinical protocol: phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer Wound Repair Regen 8 2000 480 493
9. D.J. Margolis T. Cromblehome M. Herlyn P. Cross L. Weinberg J. Filip Clinical protocol: phase I trial to evaluate the safety of H5.020CMV.PDGF-b and limb compression bandage for the treatment of venous leg ulcer: trial A Hum Gene Ther 15 2004 1003 1019
10. N. Papanas E. Maltezos Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises? Int J Low Extrem Wounds 6 2007 37 53
11. M.L. Radtke J.M. Kolesar Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support J Oncol Pharm Pract 11 2005 121 125
12. M.C. Robson T.J. Phillips V. Falanga D.J. Odenheimer L.C. Parish J.L. Jensen Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers Wound Repair Regen 9 2001 347 352
13. M.A. Siddiqui K. Wellington Palifermin: in myelotoxic therapy-induced oral mucositis Drugs 65 2005 2139 2146 discussion 2147–9
14. D.L. Steed Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers Plast Reconstr Surg 117 2006 143S 149S discussion 150S–1S
15. S. Werner T. Krieg H. Smola Keratinocyte–fibroblast interactions in wound healing J Invest Dermatol 127 2007 998 1008